0001062993-23-006089.txt : 20230306 0001062993-23-006089.hdr.sgml : 20230306 20230306171632 ACCESSION NUMBER: 0001062993-23-006089 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FOLETTA MARK G CENTRAL INDEX KEY: 0001236389 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 23709942 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2023-03-02 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001236389 FOLETTA MARK G C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 1 0 0 0 Stock Option (right to buy) 47.72 2023-03-02 4 A 0 10800 0 A 2033-03-02 Common Stock 10800 10800 D Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders. /s/ Nathaniel S. Gardiner as attorney-in-fact 2023-03-06